{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:18:54Z","timestamp":1787771934255,"version":"build-2784847793"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n                  <jats:sec>\n                    <jats:title>PURPOSE:<\/jats:title>\n                    <jats:p>This study aimed to evaluate the efficacy of ripasudil in managing various corneal edema conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS:<\/jats:title>\n                    <jats:p>\n                      This single-center retrospective analysis was conducted at Hadassah Medical Center and involved 16 patients with 17 eyes. Patients were selected based on diagnostic criteria, primarily corneal edema. The conditions were as follows, listed by frequency: postcataract surgery (31.25%), postpenetrating keratoplasty (25%), post-Descemet\u2019s membrane endothelial keratoplasty (18.75%), Fuchs\u2019 endothelial corneal dystrophy (12.5%), status post-Ahmed glaucoma valve (6.25%), and status posttrabeculectomy (6.25%). The treatment regimen involved topical administration of ripasudil hydrochloride hydrate (Glanatec\n                      <jats:sup>\u00ae<\/jats:sup>\n                      0.4%), administered three times a day or tailored to condition severity. Efficacy was assessed using pre- and posttreatment measurements of best-corrected visual acuity (BCVA), central corneal thickness (CCT), and endothelial cell count (ECC), along with slit-lamp and optical coherence tomography examinations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      The average duration of ripasudil treatment was approximately 4.9 \u00b1 2.2 months. Significant improvements were observed in BCVA, changing from a pretreatment value of 1.106 \u00b1 0.817 logMAR to a posttreatment value of 0.56 \u00b1 0.57 logMAR (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.0308). CCT also showed a significant reduction, from 619.50 \u00b1 56.36 \u03bcm pretreatment to 572.5 \u00b1 75.48 \u03bcm posttreatment (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.0479). ECC showed a marginal but not statistically significant increase, from 849.00 \u00b1 570.72 cells\/mm\u00b2 pretreatment to 874.75 \u00b1 625.59 cells\/mm\u00b2 posttreatment (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.9010).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>The study provides robust evidence supporting the use of ripasudil in managing corneal edema. Significant improvements in key ocular metrics such as BCVA and CCT were observed, enhancing the overall quality of life for patients suffering from various forms of corneal edema.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/tjo.tjo-d-23-00169","type":"journal-article","created":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T06:00:25Z","timestamp":1708408825000},"page":"88-94","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Evaluating the efficacy of Rho kinase inhibitor eye drops in the management of corneal edema: A single-center retrospective cohort study"],"prefix":"10.4103","volume":"14","author":[{"given":"Itay","family":"Lavy","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nir","family":"Erdinest","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamel","family":"Corredores","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Wajnsztajn","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Smadja","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,2,20]]},"reference":[{"key":"R1-20240830","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/ICO.0000000000002652","article-title":"Review on the use of topical ocular hypertonic saline in corneal edema","volume":"40","author":"Chow","year":"2021","journal-title":"Cornea"},{"key":"R2-20240830","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/ICO.0000000000002421","article-title":"Case series:Novel utilization of rho-kinase inhibitor for the treatment of corneal edema","volume":"40","author":"Davies","year":"2021","journal-title":"Cornea"},{"key":"R3-20240830","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s13256-021-02665-0","article-title":"Rhopressa-induced corneal edema:A case report","volume":"15","author":"Chu","year":"2021","journal-title":"J Med Case Rep"},{"key":"R4-20240830","doi-asserted-by":"crossref","first-page":"101242","DOI":"10.1016\/j.ajoc.2021.101242","article-title":"Therapeutic contact lens for fuchs endothelial corneal dystrophy:Monitoring with scheimpflug tomography","volume":"25","author":"Erdinest","year":"2022","journal-title":"Am J Ophthalmol Case Rep"},{"key":"R5-20240830","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1097\/01.ico.0000214225.98366.83","article-title":"Pseudophakic corneal edema:A review of mechanisms and treatments","volume":"25","author":"Narayanan","year":"2006","journal-title":"Cornea"},{"key":"R6-20240830","first-page":"149","article-title":"Topical hyperosmolar solutions in the reduction of corneal edema","volume":"13","author":"Insler","year":"1987","journal-title":"CLAO J"},{"key":"R7-20240830","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/ICO.0000000000000693","article-title":"Corneal tattooing and anterior stromal puncture for treating symptomatic bullous keratopathy","volume":"35","author":"Lin","year":"2016","journal-title":"Cornea"},{"key":"R8-20240830","first-page":"699","article-title":"Primary bullous keratopathy in a patient with werner syndrome treated with corneal transplant","volume":"17","author":"Singh","year":"2019","journal-title":"Exp Clin Transplant"},{"key":"R9-20240830","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1136\/bmj.333.7559.128","article-title":"Cataract and surgery for cataract","volume":"333","author":"Allen","year":"2006","journal-title":"BMJ"},{"key":"R10-20240830","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1076\/soph.17.3.110.14783","article-title":"Corneal edema after cataract surgery:Incidence and etiology","volume":"17","author":"Yi","year":"2002","journal-title":"Semin Ophthalmol"},{"key":"R11-20240830","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1186\/s12886-018-0998-5","article-title":"Quantitative evaluation of corneal epithelial edema after cataract surgery using corneal densitometry:A prospective study","volume":"18","author":"Ishikawa","year":"2018","journal-title":"BMC Ophthalmol"},{"key":"R12-20240830","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.jcrs.2014.10.033","article-title":"Oxygen therapy for corneal edema after cataract surgery","volume":"41","author":"Sharifipour","year":"2015","journal-title":"J Cataract Refract Surg"},{"key":"R13-20240830","first-page":"505","article-title":"Transient corneal edema after phacoemulsification","volume":"25","author":"Kausar","year":"2015","journal-title":"J Coll Physicians Surg Pak"},{"key":"R14-20240830","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s12886-022-02452-5","article-title":"Refractive changes and visual quality in patients with corneal edema after cataract surgery","volume":"22","author":"D\u00edez-Ajenjo","year":"2022","journal-title":"BMC Ophthalmol"},{"key":"R15-20240830","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1167\/tvst.10.4.18","article-title":"The ROCK inhibitor ripasudil shows an endothelial protective effect in patients with low corneal endothelial cell density after cataract surgery","volume":"10","author":"Fujimoto","year":"2021","journal-title":"Transl Vis Sci Technol"},{"key":"R16-20240830","doi-asserted-by":"crossref","first-page":"231","DOI":"10.26502\/fjor.2644-00240041","article-title":"Efficacy of the Rho-kinase inhibitor ripasudil for fuchs'endothelial corneal dystrophy","volume":"4","author":"Fujimoto","year":"2021","journal-title":"J Ophthalmol Res"},{"key":"R17-20240830","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/IJG.0000000000001203","article-title":"Long-term side effects including blepharitis leading to discontinuation of ripasudil","volume":"28","author":"Saito","year":"2019","journal-title":"J Glaucoma"},{"key":"R18-20240830","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1089\/jop.2019.0125","article-title":"Safety and efficacy of long-term ripasudil 0.4% instillation for the reduction of intraocular pressure in Japanese open-angle glaucoma patients","volume":"36","author":"Maruyama","year":"2020","journal-title":"J Ocul Pharmacol Ther"},{"key":"R19-20240830","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/ceo.14224","article-title":"ROCK inhibitors in ophthalmology:A critical review of the existing clinical evidence","volume":"51","author":"Karri","year":"2023","journal-title":"Clin Exp Ophthalmol"},{"key":"R20-20240830","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s40265-019-01130-z","article-title":"Rho-associated kinase inhibitors:Evolving strategies in glaucoma treatment","volume":"79","author":"Schehlein","year":"2019","journal-title":"Drugs"},{"key":"R21-20240830","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s12886-020-01490-1","article-title":"Safety and efficacy of ripasudil in Japanese patients with glaucoma or ocular hypertension:12-month interim analysis of ROCK-J, a post-marketing surveillance study","volume":"20","author":"Tanihara","year":"2020","journal-title":"BMC Ophthalmol"},{"key":"R22-20240830","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1007\/s12325-021-02023-y","article-title":"Long-term intraocular pressure-lowering effects and adverse events of Ripasudil in patients with glaucoma or ocular hypertension over 24 months","volume":"39","author":"Tanihara","year":"2022","journal-title":"Adv Ther"},{"key":"R23-20240830","first-page":"361","article-title":"Rock inhibitors:Future of antiglaucoma medication","volume":"2","author":"Vohra","year":"2014","journal-title":"Ophthalmol Res"},{"key":"R24-20240830","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/ICO.0000000000002437","article-title":"Descemet stripping only supplemented with topical ripasudil for fuchs endothelial dystrophy 12-month outcomes of the sydney eye hospital study","volume":"40","author":"Moloney","year":"2021","journal-title":"Cornea"},{"key":"R25-20240830","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ajo.2020.12.006","article-title":"Potential functional restoration of corneal endothelial cells in fuchs endothelial corneal dystrophy by ROCK inhibitor (ripasudil)","volume":"224","author":"Schl\u00f6tzer-Schrehardt","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"R26-20240830","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1097\/ICO.0000000000003282","article-title":"Topical ripasudil for the treatment of segmental corneal edema:A case series","volume":"42","author":"Tseng","year":"2023","journal-title":"Cornea"},{"key":"R27-20240830","doi-asserted-by":"crossref","first-page":"101245","DOI":"10.1016\/j.ajoc.2021.101245","article-title":"Rho-associated kinase inhibitor eye drops in challenging cataract surgery","volume":"25","author":"Antonini","year":"2022","journal-title":"Am J Ophthalmol Case Rep"},{"key":"R28-20240830","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1097\/ICO.0000000000002270","article-title":"5-year outcomes of descemet stripping only in fuchs dystrophy","volume":"39","author":"Artaechevarria Artieda","year":"2020","journal-title":"Cornea"},{"key":"R29-20240830","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1167\/iovs.17-22106","article-title":"Allogeneic Descemet's membrane transplantation enhances corneal endothelial monolayer formation and restores functional integrity following descemet's stripping","volume":"58","author":"Bhogal","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Taiwan Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/tjo.TJO-D-23-00169","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:21:37Z","timestamp":1787768497000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/tjo.TJO-D-23-00169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/tjo.tjo-d-23-00169","relation":{},"ISSN":["2211-5056","2211-5072"],"issn-type":[{"value":"2211-5056","type":"print"},{"value":"2211-5072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"2023-10-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}